Pharmacoepidemiology in Safety Evaluations of Newly Approved Medications

In the recent extension of the Prescription Drug User Fee Act, the risk management programs that are to be funded by additional user fees combine ascertainment of risks in the initial postapproval phase with activities to confront these risks. Better recognition of risks, a prerequisite for success...

Full description

Saved in:
Bibliographic Details
Published in:Drug information journal 2004-01, Vol.38 (1), p.61-67
Main Author: Gutterman, Elane M.
Format: Article
Language:English
Subjects:
Clinical trials
Pharmaceutics
Pharmacoepidemiology
Pharmacology
Pharmacovigilance
Prescription drugs
Regulatory approval
Risk management
Safety
User fees
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In the recent extension of the Prescription Drug User Fee Act, the risk management programs that are to be funded by additional user fees combine ascertainment of risks in the initial postapproval phase with activities to confront these risks. Better recognition of risks, a prerequisite for success in managing risks, will require strategies to supplement the present system of spontaneous event reporting. This overview considers the merits of pharmacoepidemiology studies in examining gaps in drug safety resulting from the inherent limitations of clinical trials. After drugs become widely used following regulatory approval, many health outcomes potentially related to drug exposures can be studied in large health insurance claims databases using pharmacoepidemiology designs tailored to this venue. We clarify types of safety investigations particularly suited to examination in a large claims database, as well as the benefits and caveats of expanding postapproval follow-up through Prescription Drug User Fee Act funding.
ISSN:2168-4790
0092-8615
2168-4804
2164-9200
DOI:10.1177/009286150403800109